“Nearly 2 billion people have no access to basic medicines, causing a cascade of preventable misery and suffering. Good health is impossible without access to pharmaceutical products.” The World Health Organization’s (WHO) ‘Access to Medicine’ report on ‘Ten years in … Continue reading
Tag Archives: Gilead
Pharma R&D: Chasing A Rainbow To Replicate The Past
Would future be always a replica of the past? If the response is yes, the efforts of many global pharma players to replicate the successful Research and Development (R&D) models of long gone by days, would continue to be a … Continue reading
New “National IPR Policy” of India – A Pharma Perspective
Whether under pressure or not, is hardly of any relevance now. What is relevant today is the fact that the new Indian Government, almost in a record time of just around two months, has been able to release a high … Continue reading
An Aggressive New Drug Pricing Trend: What It Means To India?
A new class and an aggressive drug-pricing trend is now evolving in the global pharmaceutical industry, exerting huge financial pressure on the patients and payers, including governments, especially, in the developed nations of the world. Another aspect of this issue … Continue reading
Gilead: Caught Between A Rock And A Hard Place In India
I had mentioned in my blog post of August 4, 2014, titled “Hepatitis C: A Silent, Deadly Disease: Treatment beyond reach of Most Indians” that in line with Gilead’s past approach to its HIV medicines, the company would offer to … Continue reading
Patented Drug Pricing: Relevance To R&D Investments
The costs of most of the new life saving drugs, used in the treatment of dreaded diseases such as cancer, have now started going north at a brisk pace, more than ever before. From the global pharma industry perspective, the … Continue reading
Hepatitis C: A Silent, Deadly Disease: Treatment Beyond Reach of Most Indians
Every year, July 28 is remembered as the ‘World Hepatitis Day’. In India, this year too, the day had gone by virtually uneventful, for various reasons. This happened despite increasing trend of the disease in the country. Though, there are … Continue reading
Leading Through The Challenge Of Change: Is Pharma Leadership Too Archaic?
A recent major global survey titled “Testing The Health Of The Pharmaceutical Industry” has revealed that a sizable majority of executives polled, though believe the sector is in good shape, are concerned of its reputation. Interestingly, 73 percent of respondents believe … Continue reading